The SYNC-T solid tumor immunotherapy platform is personalized and performed in situ (within the body).  It is a first-in-class therapy that uniquely combines partial oncolysis (breakdown) of a small part of the tumor followed by infusion of a multi-target biologic drug directly into the tumor. This method is designed to simultaneously address numerous immune suppression mechanisms while also being immunostimulatory. The synergistic approach aims to educate the immune system to recognize and attack cancer throughout the body.